Br J Cancer: The medicinal level IgG weakens the anti-cancer activity of Osaliplat against colon cancer cells

Oxaliplatin is a third-generation platinum anti-cancer drug.
, compared to other platinum derivatives such as cisplatin and carbapene, the amine base of Osali platinum is replaced by dhamyl cyclohexane, which inhibits DNA synthesis more quickly and efficiently.
previous preclinical studies have shown that in colon cancer, the combined use of Osaliplatin with 5-fluorouracil (5-fluorouracil) can produce a synergetic anti-cancer effect.
And clinically, the addition of Osaliplatin to the treatment combination of 5-fluorouracil and folate (methyl tethydrofolic acid, leucovorin) (FOLFOX program) significantly improves the survival rate of colon cancer patients, while the treatment option containing Oshali platinum has become a standard of treatment for colon cancer.
immunoglobulin G (IgG) is one of the most common types of antibodies produced and secreted by plasma B cells.
in clinical practice, IgG supplementation is particularly beneficial for patients with inflammatory diseases.
because inflammation has been recognized as an emerging marker of cancer development, more and more clinical trials are trying to assess the benefits of anti-inflammatory strategies in cancer treatment.
previous studies have shown that cytotoxic chemotherapy impairs the function of the immune system until severe immunodeficiency occurs.
some cancer patients may need to supplement IgG to compensate for the latter.
recent evidence that intravenous IgG impairs the viability of cancer cells, however, there is no research to assess whether IgG is beneficial to cancer patients undergoing chemotherapy.
study aims to explore the effects of medicinal-grade human-sourced IgG on the vitality of colon cancer cells from a range of patient sources with/without chemical intervention.
the effects of cell death through a flow cytometer.
, the researchers assessed the effects of Osaliplatin and IgG on the ERK1/2 signaling path, at protein levels.
medicinal level IgG reduced Osali platinum-induced cell death by evaluating the combination of medicinal levels IgG (such as PRIVIGEN®IgG and Tonglu®IgG) with chemotherapy, the researchers did not directly observe any significant effect of IgG on tumor cell viability.
, however, the researchers found that IgG significantly impaired the anti-tumor effects of Osaliplatin.
the primary cancer cell line is able to express IgG's inhibitor and accumulate IgG in the cell.
addition, although Osali platinum induces the activation of ERK1/2, IgG inhibits the activity of ERK1/2.
, the results show that medicinal grade IgG can impair the anti-cancer activity of Osali platinum.
data also strongly suggest that therapeutic IgG as a combined drug may have some harmful side effects on cancer patients.
these preclinical observations also provide a basis for further preclinical and epidemiological and clinical studies.